To hear the full episode, become a patron at petriam.com slash netpanel pod.

So what they literally say in this marketing document is deprecote could very easily capture a much larger market as a sedative of choice essentially within the nursing home system because nursing homes would not have to, as it mentions,

be documented as appropriate for the diagnosis,

attempt to reduce the dose or eliminate the use of them over the course of six months,

or be given for the appropriate indication or even dosage, right?

So this is fun.

And that OBRA restriction, that's there talking about specifically the 1987 laws, which

restricted the ways that, you know, antipsychotics could be used.

But DeBocote was FDA approved as an anti-seizure medication that has these side effects that are similar to

antipsychotics but are, you know, regulated differently. And because of the way that the law was

passed initially being so short-sighted and so limited, it really imposed little to no restriction

on this practice at all. But it definitely quelled the public outrage. I'll give it that. You know, Reagan did a good job with quelling public outrage at this practice at all, but it definitely quelled the public outrage. I'll give it that.

You know, Reagan did a good job with quelling public outrage at this practice and pushing it

under the rug for another 10 years. Yeah. The other really important thing that it gives

context just to understand how, like the scale of what happens here um is that within this marketing document itself

you see that they're very specifically it's you know we're not just saying like oh there's a

you know this happens all the time there's a big market for it like let abbott laboratories tell

you basically because they're identifying right because you know they have a they have the

rights to this drug and they're

identifying, well, deprecote could be used more, right? That's what the, but that's what, that's what, that's what statements like, well, you know, nursing homes, it could be really convenient for them to prescribe this because they wouldn't have all these, you know, quote unquote burdensome reporting requirements over it, right? And so, like here's how they report the scale

and remember this is 1998

and the I mean reporting requirements over it, right? And so, like, here's how they report the scale. And remember,

...